Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 224 participants.

Also called NCT02538978

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 224 participants (planned count) (from the registry)
Sponsor
Cesca Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT02538978
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02538978. Randomized; quadruple masking; primary purpose treatment. Start 2017-01 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System
Acronym
CLIRST III
Condition
Critical Limb Ischemia (CLI)
Intervention (Biological)
Autologous Bone Marrow Concentrate (aBMC)
Intervention (Biological)
Placebo Control (diluted autologous peripheral blood)
Lead sponsor
Cesca Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02538978
Content hash
c6152b05f3bcff0213cfc5a89abeecf9bc4da9d0c321ec47067189a6c84f4889